Suven Life Sciences (Suven) has been granted one product patent from Europe (2507225) and two product patents from Eurasia (023293 and 023260) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029, 2030 and 2031 respectively.
The granted claims of the patents are from the mechanism of action include the class of selective 5?HT4 compounds, Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
With these new patents, the company has a total of twenty one granted patents from Europe and nineteen granted patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out?licensed at various phases of clinical development like at Phase?I or Phase?II.
